Clinical Trial Update: A Study on Spermatogenesis in Male Renal Transplant Recipients Receiving Valganciclovir (Valcyte®) Versus Untreated Matched Controls [Phase 4]

View source ↗

Summary

Phase 4 clinical trial comparing spermatogenesis outcomes in male renal transplant recipients treated with valganciclovir (Valcyte) versus untreated controls; r…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cytomegalovirus Infection in Transplant Recipients
• Renal Transplant-related Cytomegalovirus Infection

Drugs mentioned

• Valganciclovir (Valganciclovir)

Snippet

Sponsor: Hoffmann-La Roche | Conditions: Cytomegalovirus Infections | Phase 4 | Status: COMPLETED | Results posted: 2018-08-31